CClinicalTrials.gg
Status unknownNCT01658592Updated Aug 7, 2012

Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule for Severe Alcohol Addiction

An interventional study of Deep brain stimulation and Placebo in Addiction, sponsored by Guodong Gao. Status unknown at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-08-07.

Sponsored by Guodong Gao · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the nucleus accumbens (NAc) and the ventral anterior internal capsule (VC) as a novel treatment in severe alcohol addiction. The included patients have been treated so far with drugs that inhibits alcohol, or psychological behavior training.

Our hypothesis is that bilateral NAc-VC DBS will significantly reduce the craving for alcohol and thus enable the patients to decrease their alcohol intake substantially.

Read the detailed description

The nucleus accumbens (NAc) is considered associating with addiction. The ventral anterior internal capsule(VC) is proved a effective target to obsessive compulsive disorder(OCD). Like other addiction behaviors most alcohol addicts contain obsessive compulsive symptom. We explored an operation method, that is, in the Leksell stereotactic positioning system take VC as the point of entry, take NAc as the point of target, then make sure that the distance between entry and target points are included in the four contacts of electrode of DBS. When stimulator is ON the investigators can adjust parameters so that the coverage of electrode contains both Vc and NAc. The investigators suppose that bilateral NAc-VC DBS will significantly reduce the craving for alcohol and thus enable the patients to decrease their alcohol intake substantially.

02

Conditions studied

  • Addiction

Keywords

  • Alcohol Addiction;
  • Deep Brain Stimulation;
  • Nucleus Accumbens;
  • Ventral Anterior Internal capsule;
03

In context

Alcoholism

1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's planned enrollment of 20 is below the median of 87 across 1,371 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

This is the only study on the registry with Guodong Gao as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age > 18 years
  • Long lasting alcohol addiction (fulfilled diagnostic-criteria according to DSM-IV,ICD-10)
  • At least one detoxication-treatment without a long-term period of abstinence has already taken place
  • Long-term inpatient treatment to support abstinence have occurred
  • Free patient's decision / Informed Consent (existing comprehensive ability in meaning, methodology and execution of the study and ability of acceptance)
  • If prior medication, stable dosage of psychopharmacological drugs over the last three months, which shall, after checking be retained during the study

Exclusion criteria

Exclusion Criteria:

  • Hospitalization for psychotic symptoms
  • Clinical relevant psychiatric comorbidity (such as schizophrenic psychoses, bipolar affective diseases, severe personality disorder, and so on. And diagnosed by criteria according to DSM-IV,ICD-10)
  • Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/ heart defibrillator
  • Current and in the last six months existent paranoid-hallucinated symptomatology
  • Foreign aggressiveness in the last six months
  • Verbal IQ \< 85 (evaluated with the Wechsler Adult Intelligence Scale- Chinese Revised (WAIS-CR)
  • Stereotactic respectively neurosurgical intervention in the past
  • Other neurological diseases
  • Contraindications of a stereotactic operation, e.g. increased bleeding-disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases)
  • Serious and instable organic diseases (e.g. instable coronal heart disease)
  • tested positively for HIV
  • pregnancy and/or lactation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    NAC-VC Deep Brain Stimulation

    The contractors located in NAc and VC are ON at the same time

    Other: Deep brain stimulation · Other: Placebo

  • Sham comparator
    Placebo A

    Stimulator setting is OFF

    Other: Deep brain stimulation · Other: Placebo

  • Experimental
    Placebo B

    The contractor located in NAc is on

    Other: Deep brain stimulation · Other: Placebo

  • Experimental
    Placebo C

    The contactor located in VC is on

    Other: Deep brain stimulation · Other: Placebo

Interventions

  • OtherDeep brain stimulation

    Stimulator setting is ON

  • OtherPlacebo

    Stimulator setting is OFF

06

What researchers measure

Primary outcomes

  1. Reduction of Alcohol

    Reduction of the dosage of alcohol(all kinds of liquor were converted into pure alcohol) comparing baseline and the particular ward rounds during and at the end of the crossover-design.

    Time frame: 7 months

Secondary outcomes

  1. Craving

    10-point visual analog scale (VAS) of craving

    Time frame: 7 months

Other outcomes

  1. Psychological components

    Addiction severity(ASI); Psychological components (Anxiety (BAI-21 item); Depression (BDI-21 item); Quality of life (WHOQL-Brief); Health condition(SF-36).

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
  • Department of neurosurgery, Tangdu Hospital
    Xi'an, Shaanxi 710038, China
    • Gao G Dong, Doctor · Contact · gguodong@fmmu.edu.cn · +86 29-84777435
    • Wang X Lian, Doctor · Contact · tdwxlian@126.com · +86 29-84777284
    • Wang X Lian, Doctor · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01658592
Lead sponsor
Guodong Gao
Collaborators
Tang-Du Hospital
Responsible party
Guodong Gao (Neurosurgery Department, Tang-Du Hospital) — Sponsor-investigator
First posted
Aug 7, 2012
Start date
Jul 2012
Primary completion
Mar 2014 (estimated)
Completion
Mar 2014 (estimated)
Last update
Aug 7, 2012

Study contacts

Gao G Dong, Doctor
Contact
gguodong@fmmu.edu.cn
+86 29-84777435
Wang X Lian, Doctor
Contact
tdwxlian@126.com
+86 29-84777284
Gao G Dong, Doctor
principal investigator · Department of neurosurgery, Tangdu Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion